NasdaqGM:HROWPharmaceuticals
How Investors Are Reacting To Harrow (HROW) Reaffirming 2025 Revenue Guidance After Strong Q2 Results
Earlier in August 2025, Harrow, Inc. reported strong second quarter results, with quarterly revenue rising to US$63.74 million and net income moving into positive territory, followed by management reaffirming that full-year 2025 revenue is expected to exceed US$280 million.
This suggests the company is confident in its growth trajectory, expecting to generate around US$169 million in revenue in the second half to meet its target for the year.
We'll examine how Harrow's reaffirmed revenue...